Clascoterone's full trial results are expected by mid-July 2026, but skepticism exists about timely release. Clascoterone is available at 5% from some telehealth companies.
The conversation is about finding a reasonably priced shampoo with piroctone olamine in the US. The user is cautious about trying new or smaller brands.
PP405 is discussed as a potential hair growth stimulant, possibly more effective than minoxidil, but not a cure for hair loss. There is skepticism about its ability to regrow "deadzones," and concerns about its impact on those with hair transplants.
The conversation discusses the potential of Replicel/Shiseido treatment for hair loss, questioning its effectiveness, whether it grows new follicles, and its market release timeline. It also compares Replicel to other competitors like Kyocera/RIKEN/Tsuji.
The conversation is about a user seeking information on a clinical trial by Amplifica - Scube3 for Androgenetic Alopecia (AGA). The user is unsure if it's a formal phase 1 study.
The conversation discusses concerns that Anagenic's version of GT20029 might not be as effective or safe as Kintor's, with comparisons to issues faced by pyrilutamide. The chemical structure of the drug has been published.
The conversation discusses Kintor's initiation of a new Phase 3 trial to assess the long-term safety of Pyrilutamide (KX-826) for hair loss, which will last 52 weeks. Specific treatments mentioned include Pyrilutamide.
PP405 is a potential hair loss treatment showing promise, especially for men with severe balding. Some are hopeful it will be a game-changer for those who cannot tolerate finasteride or minoxidil, despite skepticism about the outcomes.
A 35-year-old shared a 2-month update on their hair transplant of 3153 grafts, noting redness, itching, and some pimples, while using finasteride for over 12 years to maintain hair. Users discussed the effectiveness and timing of starting finasteride, with some suggesting consulting a doctor for young individuals considering the treatment.
Clascoterone is a topical treatment for androgenetic alopecia, showing modest to moderate hair regrowth, and may be available by 2027-2028. It is considered safer than finasteride, with discussions on its effectiveness compared to RU58841 and pyrilutamide.
A satirical discussion about a hair transplant, with humorous comments on graft placement and clinic choice. The conversation includes references to a "Rebuild a Scalp Clinic" and jokes about using pubic hair and overharvesting.
The conversation is about someone using finasteride and minoxidil along with microneedling as a treatment for hair loss, and there's a mention of scalp tattooing as an alternative or additional approach. Some responses mock the approach, while others inquire about the specifics of the treatment and its effectiveness.
The conversation is about finding a reputable place to buy Clascoterone in the US. An alternative treatment, pyrilutamide, is suggested as a strong and official option.
PP405 is viewed skeptically, with some seeing it as overhyped and potentially ineffective compared to existing treatments like minoxidil and finasteride. While it shows some promise in activating dormant hair follicles, many believe it won't replace hair transplants or significantly outperform current options.
Copper peptides are discussed as a potential treatment for hair loss, with various products and serums suggested, including those from Peptonix and The Ordinary. Some users express skepticism about the effectiveness and concentration of copper peptides in these products.
The conversation discusses the anticipation of Chinese manufacturers producing Clascoterone 5% before its full approval in 2027. It also mentions treatments like Minoxidil, finasteride, and RU58841 for hair loss.
The conversation discusses a new product from Actifolic, which combines RU58841 and GHK-CU for hair loss treatment. The participants are considering whether it's worth trying.
A 28 year old using a hair loss prevention protocol to restore thinning hair, which includes finasteride, dutasteride, minoxidil, stemoxydine, alopecin, nizoral shampoo and microneedling; the user is now adding pyrilutamide solution to the regimen with the hope of improving their results. RU58841 was also ordered but not yet used.
A 35-year-old man had a 6400 graft hair transplant in Turkey after years of baldness, using finasteride, oral and topical minoxidil, and scalp micropigmentation. He is satisfied with the progress and plans further SMP touch-ups to enhance results.
The post discusses the user's experience with hair loss treatment RU58841, which was tested for quality and found to be 96+% pure. The conversation includes various responses, with some users questioning the safety of the product and others expressing satisfaction with the test results.
PP405 may revive dormant hair follicles but is unlikely to help with long-term baldness where follicles are replaced by scar tissue. It is seen as a potential adjunct to treatments like minoxidil and finasteride, but its effectiveness on deeply fibrotic or scarred areas is doubtful.
The conversation discusses hair loss treatments, specifically Setipiprant, finasteride, and bimatoprost. Setipiprant is suggested for maintenance, while bimatoprost is for regrowth, and combining them with dermarolling is recommended for better results.
A user shared an 8.5-month update on their hair transplant of 1064 grafts done by Dr. Kaan Pekiner in Ankara, Turkey, costing $3500. They are also using finasteride 2.25 mg weekly and have reduced shampoo use.
A user underwent a second hair transplant for increased density and to address hair loss in the crown area, with 3,800 grafts at a cost of 2,200 euros at Estepalace, including additional services. Some commenters discussed the appearance of the hairline and the importance of using DHT blockers like finasteride or dutasteride post-transplant.
Post Finasteride Syndrome (PFS) may result from epigenetic changes and gut microbiota alterations. Supplementing with Allopregnanolone might protect against these adverse effects.
PP405 is a potential hair loss treatment, but its safety and effectiveness are uncertain. Users advise caution and suggest waiting for more data before purchasing unverified versions.
The GT20029 tincture, a topical androgen receptor degrader, showed significant hair growth and good safety in a China Phase II trial for male androgenetic alopecia (AGA), with the 1% dose twice weekly identified as optimal. The company plans to initiate Phase III trials in China and Phase II in the U.S., and the treatment also shows promise for acne.
A user shared their experience with DIY PRP scalp injections for hair regrowth, using an EZ Injector and other at-home equipment. Another user reported success with at-home PRP treatments for 1.5 years, noting thicker hair and a stable hairline.
A user was recommended PRP and exosomes for hair loss and asked about combining them and places to get the treatment in the UK. Other users suggested starting with finasteride and minoxidil due to the high cost and variable success of PRP and exosomes.